Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics develops long-acting antibody therapies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A and IL-23, with programs such as SPY001, SPY002 and SPY003 evaluated as monotherapies and pairwise combinations.
Recurring news for Spyre Therapeutics includes clinical updates from the SKYLINE platform trial in ulcerative colitis and the SKYWAY basket trial in rheumatic diseases, financial results and corporate updates, common-stock financing activity, and equity inducement awards under its 2018 Equity Inducement Plan. Company announcements also describe balance-sheet actions, development priorities and data presentations tied to its immune-mediated disease pipeline.
Spyre Therapeutics (NASDAQ: SYRE) announced management will participate in three investor conferences in March 2026: TD Cowen Health Care (Boston) on March 3, Leerink Global Healthcare (Miami) on March 9, and Jefferies Biotech on the Beach (Miami) on March 10.
Management will host one-on-one investor meetings and provide live audio webcasts and replays via the company investor events website.
Spyre Therapeutics (NASDAQ:SYRE) reported Q4 and full-year 2025 results and corporate updates on Feb 19, 2026. Key highlights: $756.5 million in cash and marketable securities as of Dec 31, 2025, expected runway into H2 2028; six proof-of-concept readouts planned in 2026 across SKYLINE and SKYWAY.
The company advanced SPY001, SPY002, SPY003, and SPY072 into Phase 2 trials, raised gross proceeds of $316.2 million in Oct 2025, and appointed a new Chief Commercial Officer.
Spyre Therapeutics (NASDAQ: SYRE) announced scientific presentations at the 21st ECCO Congress (Feb 18-21, 2026) covering interim Phase 1 results for SPY003, the SKYLINE platform trial, and preclinical mouse data showing dual TL1A/IL-23 targeting outperformed monotherapies.
SPY003 was well tolerated to 20 weeks, showed a differentiated PK profile consistent with Q3M or Q6M dosing, and reduced downstream cytokines.
Spyre Therapeutics (NASDAQ: SYRE) granted inducement stock options totaling 30,200 shares to five non-executive employees under its 2018 Equity Inducement Plan.
Approved on Feb 2, 2026, the options have a 10-year term, $32.75 exercise price (Feb 2 close) and vest 25% after one year then monthly at 1/48th, subject to continuous service.
Spyre Therapeutics (NASDAQ: SYRE) announced that its Compensation Committee approved inducement stock options to purchase 108,155 shares for employee Kate Chevlen in connection with her appointment as Chief Commercial Officer.
The grant was approved on January 22, 2026, provided under the 2018 Equity Inducement Plan, and was disclosed as material to the employee's acceptance under Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $34.09, equal to Spyre's Nasdaq closing price on January 22, 2026. Vesting is 1/4 on the first anniversary of the start date, then 1/48 monthly thereafter, subject to continuous service and the 2018 Plan terms.
Spyre Therapeutics (NASDAQ: SYRE) outlined a 2026 plan anchored by six expected proof-of-concept (POC) readouts: three from the SKYLINE Phase 2 platform in ulcerative colitis and three from the SKYWAY Phase 2 basket trial in RA, PsA, and axSpA. Enrollment for SKYLINE Part A exceeded expectations with SPY001 enrollment complete and Part A readouts now anticipated to begin in Q2 2026. SKYWAY readouts across all indications are expected in 4Q 2026. The company appointed Kate Tansey Chevlen as Chief Commercial Officer and reported a pro forma cash, cash equivalents, and marketable securities balance of $783M as of Sept 30, 2025, which it expects to fund operations into the second half of 2028.
Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 42,000 shares granted to six non-executive employees under the 2018 Equity Inducement Plan. The grants were approved on January 2, 2026 and were described as material to each employee's acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a 10-year term, an exercise price of $30.58 (Spyre closing price on January 2, 2026), and vest one-fourth on the first anniversary of each employee’s start date with the remainder vesting monthly at 1/48th thereafter, subject to continuous service and the terms of the 2018 Plan.
Spyre Therapeutics (NASDAQ: SYRE) announced that its independent Compensation Committee approved inducement stock option awards to two non-executive employees under the Spyre 2018 Equity Inducement Plan.
The awards total 20,300 options, were approved on December 1, 2025, have a 10-year term, and an exercise price of $28.66 (Nasdaq closing price on December 1, 2025). Vesting is one-quarter on the first anniversary of each employee’s start date and then 1/48th monthly thereafter, subject to continuous service; the options are subject to the 2018 Plan and were described as material to each employee’s acceptance under Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics (NASDAQ: SYRE) announced that its independent Compensation Committee approved inducement stock options for 19,600 shares to one non-executive employee under the 2018 Equity Inducement Plan. The grants were approved on November 3, 2025, have a 10-year term, and an exercise price equal to the $23.78 Nasdaq closing price on November 3, 2025. Vesting is one-fourth on the first anniversary of the employee’s start date and then 1/48th monthly thereafter, subject to continuous service. The options were described as material to the employee’s acceptance of employment under Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics (NASDAQ:SYRE) reported Q3 2025 results and program updates on Nov 4, 2025. Key developments include positive Phase 1 interim data for SPY003 (IL-23) showing a ~85-day half-life supporting quarterly or twice‑annual dosing, and interim Phase 1 data for SPY002/SPY072 showing complete TL1A suppression through up to 20 weeks.
The company initiated the SKYWAY Phase 2 basket trial (SPY072) in Sept 2025 and the SKYLINE Phase 2 platform (SPY001/SPY002; SPY003 expected soon). Spyre expects six Phase 2 proof‑of‑concept readouts in 2026. Financings: $316M gross from an underwritten offering and pro forma cash of $782.7M as of Sept 30, 2025, with expected runway into H2 2028.